Not exact matches
The current
standard of care for advanced pancreatic cancer — a combination of nab - paclitaxel and
gemcitabine — was developed by TGen and the HonorHealth Research Institute, and approved by the U.S. Food and Drug Administration in 2013.
The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with
standard therapy or following administration of either brentuximab vedotin or
gemcitabine alone.
All but one of the ten patients transitioned to treatment with
gemcitabine, which is a
standard therapy for pancreas cancer.
Each patient will receive
gemcitabine and nab - paclitaxel, two chemotherapy drugs that are
standard of care.